A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 13
- 主要终点
- Total Kidney Volume
研究概览
简要总结
ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening). Administration will be continued until the time of manufacturing and distribution approval of OPC-41061 for ADPKD in Japan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002)
- •Patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up.
排除标准
- •Patients with eGFR of less than 15 mL/min/1.73 m2
- •Patients with any of the following complications:
- •Uncontrolled hypertension
- •Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)
- •Patients with any of the following complications or history thereof:
- •Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity
- •Inability to personally give consent due to a mental illness
研究组 & 干预措施
OPC-41061
Repeated oral administration at doses of 15 mg twice daily (morning and evening)
干预措施: OPC-41061 (Drug)
结局指标
主要结局
Total Kidney Volume
时间窗: Baseline, Week 48, 96, 144, and 192
Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period. Repeated oral administration at doses of 15 mg twice daily (morning and evening) until approval of the revised protocol (Edition 4.0) by the IRB of each trial site. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
Renal Function Test (eGFR)
时间窗: Baseline, Week 48, 96, 144, and 192
Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
次要结局
未报告次要终点